1. Home
  2. Directory
  3. Minnesota
  4. Austin
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1164529384

DR. GARETH SHIGEMI HATAYE OD
Prescription History 1164529384
Optometrist in Austin, MN

NPI Status: Active since September 20, 2006

Contact Information

318 N MAIN ST
AUSTIN, MN
ZIP 55912
Phone: (507) 437-7768
Fax: (507) 437-7769

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. GARETH SHIGEMI HATAYE OD, an active Optometrist specialist practicing in Austin, MN. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 157 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 76 claims alone.

Medication Index

B
D
L
R
T
No matching medications currently found on file.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 11
30-Day Fills 16.8
Days Supply 502
MN State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills93.6
Peer Average Days Supply2,695
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.2% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $126.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.54

State Avg Cost Per Claim

$50.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 13
30-Day Fills 27.2
Days Supply 815
MN State Average Benchmarks
Peer Average Claims71.0
Peer Average 30-Day Fills146.9
Peer Average Days Supply4,392
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.7% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $416.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.07

State Avg Cost Per Claim

$32.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 76
30-Day Fills 157.7
Days Supply 4,646
MN State Average Benchmarks
Peer Average Claims126.0
Peer Average 30-Day Fills229.1
Peer Average Days Supply6,552
Conservative Utilization

This provider writes prescriptions for this formulation 39.7% less frequently than the standard regional baseline metric for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,698.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.50

State Avg Cost Per Claim

$21.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 17
30-Day Fills 20.5
Days Supply 570
MN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills57.3
Peer Average Days Supply1,673
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,938.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$584.62

State Avg Cost Per Claim

$1,066.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 40
30-Day Fills 102.6
Days Supply 3,076
MN State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills138.8
Peer Average Days Supply4,106
Conservative Utilization

This provider writes prescriptions for this formulation 39.4% less frequently than the standard regional baseline metric for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $648.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.22

State Avg Cost Per Claim

$19.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. GARETH SHIGEMI HATAYE OD provides transparency into local medical care patterns within Austin, MN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.